At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 142 enrolled
Drug / intervention
Suvorexant 20 mg +1 moredrug
Likely dose
Suvorexant 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Suvorexant to Improve Postoperative Sleep and Reduce Delirium Severity in Older Surgical Patients: A Double-blinded, Randomized, Placebo-controlled Trial
In Brief
A Phase 2 clinical trial evaluating Suvorexant 20 mg and Placebo for Delirium in Old Age. Completed, enrolled 142 participants across 1 site.
Detailed Summary
This research study will evaluate the effectiveness of postoperative administration of a drug called suvorexant, to improve postoperative sleep and decrease the severity of delirium (serious confusion) in adults 65 years and older undergoing non-cardiac surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDelirium in Old Age
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
202420252026
First PostedFeb 2023
Enrollment StartJun 2023
Primary CompletionJun 2025
Study CompletionJul 2025
TodayJul 2026
First PostedFeb 17, 2023
Enrollment StartJun 28, 2023
Primary CompletionJun 25, 2025
Study CompletionJul 7, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.4 years ago
Interventions
Suvorexant 20 mgdrug
Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
Placebodrug
Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2